baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Intellia Therapeutics Inc/ US45826J1051 /

2024-05-07 9:35:07 PM	Chg. +0.2850	Volume	Bid9:35:11 PM	Ask9:35:11 PM	High	Low
24.0050USD	+1.20%	492,050 Turnover: 6.97 mill.	24.0000Bid Size: 300	24.0100Ask Size: 100	24.0450	23.2900

GlobeNewswire 05-02 Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Upd...

GlobeNewswire 04-29 Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of...

GlobeNewswire 03-18 Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a...

GlobeNewswire 02-22 Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights R...

GlobeNewswire 02-15 Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene...

GlobeNewswire 02-14 Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings ...

GlobeNewswire 01-31 Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patien...

GlobeNewswire 01-24 SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmento...

GlobeNewswire 01-04 Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milest...

GlobeNewswire 01-02 Tome Biosciences Acquires Replace Therapeutics

GlobeNewswire 2023-12-12 Tome Biosciences Launches with Over $200 Million in Funding to Advance Programmable Genomic Integrat...

GlobeNewswire 2023-11-14 Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigatio...

GlobeNewswire 2023-11-09 Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company P...

GlobeNewswire 2023-11-07 Maravai LifeSciences Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-11-03 Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blo...

GlobeNewswire 2023-11-02 Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th Internatio...

GlobeNewswire 2023-11-02 Regeneron Reports Third Quarter 2023 Financial and Operating Results

GlobeNewswire 2023-10-26 Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatm...

GlobeNewswire 2023-10-18 Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initi...

GlobeNewswire 2023-10-13 Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Ag...

GlobeNewswire 2023-10-03 Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies fo...

GlobeNewswire 2023-08-30 SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phas...

GlobeNewswire 2022-03-09 Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of A...

GlobeNewswire 2022-03-01 Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for th...

Intellia Therapeutics Inc/ US45826J1051 /

If you wish to receive reply to your feedback, please provide your email address.